Physician profile
James E Kenney
NPI 1639177249
$3,540.76
in general payments reported to CMS, 2019-2025
35 companies · $293 in 2025
The $293 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $501 · 2020: $331 · 2021: $838 · 2022: $728 · 2023: $502 · 2024: $346 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,141.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $612.26 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Preventric Diagnostics, INC. | $351.87 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $289.94 | 2019-2024 | Farxiga, Breztri |
| Pfizer INC. | $278.83 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $263.90 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $220.26 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $203.99 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $202.16 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $159.48 | 2019-2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $76.32 | 2021-2023 | Eliquis |
| Global Blood Therapeutics, INC. | $63.97 | 2020-2022 | |
| Abbott Laboratories | $59.22 | 2022-2023 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $57.41 | 2020 | |
| Exact Sciences Corporation | $56.90 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sk Life Science, INC. | $53.67 | 2021-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.07 | 2024-2025 | Caplyta |
| Ucb, INC. | $48.11 | 2019 | |
| Merck Sharp & Dohme LLC | $46.03 | 2021-2024 | Verquvo |
| Otsuka America Pharmaceutical, INC. | $44.30 | 2023 | Rexulti, Nuedexta |
| Abbvie INC. | $37.75 | 2023-2025 | |
| Amgen INC. | $36.37 | 2019-2025 | Krystexxa |
| Lundbeck LLC | $34.18 | 2024 | Rexulti |
| Lifescan, INC. | $34.09 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.87 | 2019 | |
| Acadia Pharmaceuticals INC | $31.75 | 2019-2020 | |
| Amarin Pharma, INC. | $28.21 | 2020-2021 | |
| Ardelyx, INC. | $27.01 | 2024 | Ibsrela |
| Medtronic, INC. | $23.01 | 2025 | Inceptiv |
| Corcept Therapeutics | $21.83 | 2025 | Korlym |
| Shield Therapeutics INC | $18.55 | 2023 | Accrufer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.29 | 2024 | |
| Neurocrine Biosciences, INC. | $16.07 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $16.01 | 2022 | |
| Cmp Pharma, INC. | $13.08 | 2021 | |
| Avanir Pharmaceuticals, INC. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Kenney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.